LUNG CANCER

Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.

The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.

A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.

Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.

Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.

A case of a 64-year-old man with non–small cell lung cancer, who tested positive for an EGFR exon 20 insertion mutation after progression on frontline therapy.

Trastuzumab deruxtecan for the treatment of patients with unresectable or metastatic non–small cell lung cancer has been granted priority review by the FDA.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with MET-mutated non–small cell lung cancer.

Anetumab ravtansine did not show superior progression-free survival or overall survival in the second-line treatment setting for patients with mesothelin-expressing malignant pleural mesothelioma, according to results from the 15743 study.

Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.

Targeting multiple immune cell pathways may elicit better major pathologic and pathologic complete responses in patient with resectable, early-stage non–small cell lung cancer versus immune checkpoint inhibition alone.

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.

Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

The PROPHETIC trial of a predictive diagnostic analysis platform expanded to a new site at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

Acclaim-2 has opened enrollment for patients with late-stage non-small cell lung cancer and will begin screening patients for their eligibility to participate in the trial.

The combination of RBN-2397 and pembrolizumab has been dosed in the first patient with squamous cell carcinoma of the lung who is enrolled in a new phase 1b/2 clinical trial.

Use of trilaciclib prior to chemotherapy demonstrated a substantial burden of myelosuppressive hematologic adverse events within the patients with extensive-stage small-cell lung cancer.

A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Findings show adjuvant pembrolizumab to significantly improve disease-free survival in patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression

Solange Peters, MD, PhD, discusses the ways in which oncologists can manage toxicities in patients with unresectable malignant pleural mesothelioma.

The FDA has approved the FoundationOne CDx as a companion diagnostic to identify patients with non–small cell lung cancer with tumors that harbor EGFR exon 19 deletions or exon 21 substitutions.